The current study identified ETV5 as a biomarker of 5-FU-based adjCTX response in colon cancer patients with evidence II level as defined by Simon et al. (2009), and revealed that higher ETV5 is associated with poor response in patients. This evidence concerns the gene ETV5 and malignant colon neoplasm.